Novel Combinations for Lymphoma: Maximizing the Impact of Targeted Therapies
This program is sponsored by the Cleveland Clinic Center for Continuing Education and supported by Allos Therapeutics and Millenium Pharmaceuticals, Inc.
| Location: |
Peabody Orlando Hotel, Orlando Ballroom |
| Speakers: |
Stephen Smith, MD, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
Barbara Pro, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Kieron Dunleavy, MD, National Cancer Institute, National Institutes of Health, Bethesda, MD
Christian Geisler, MD, Rigshospitalet, Copenhagen, Denmark
Anton Hagenbeek, MD, PhD, Academic Medical Center, Amsterdam, Netherlands
Christopher R. Flowers, MD, Emory University Hospital, Atlanta, GA
|
This symposium will focus on understanding the pathobiology of lymphoma, which has yielded an array of new targets for drug therapies. These targets must be addressed simultaneously, as the malignant phenotype of lymphoma results from interacting epigenetic, genetic, and protein-level abnormalities. Speakers will discuss the key pathways of lymphoma cell growth, differentiation, signaling apoptosis, and resistance to chemotherapy. Emerging strategies that target these interrelated pathways using novel combinations of targeted therapies will be discussed.
Contact: Roberta Stavole, Cleveland Clinic Center for Continuing Education
Phone: 216-448-0789
Fax: 216-448-0784
E-mail: stavolr@ccf.org
back to top
State of the Art: B-Cell and T-Cell Lymphoma Management
This program is sponsored by the Educational Concepts Group, LLC, and supported by Celgene Corporation and Therakos, Inc.
| Location: |
Orange County Convention Center, Valencia A |
| Speakers: |
Michael E. Williams, MD, University of Virginia School of Medicine, Charlottesville, VA
Randy Gascoyne, MD, BC Cancer Agency and BC Cancer Research Centre, BC, Canada
Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern, Chicago, IL
Stephan Ansell, MD, PhD, Mayo Clinic Cancer Center, Rochester, MN
Craig Moskowitz, MD, Cornell University Medical College, New York, NY
Kerry Savage, MD, University of British Columbia, BC, Canada
Jasmine Zain, MD, NYU Cancer Institute, New York, NY
|
This unique program provides an ideal forum for sharing information and ideas about new approaches to B-cell and T-cell lymphoma management. Presented by prominent, well-respected opinion leaders in lymphoma, this live, independent educational program will provide medical oncologists, hematologists, hematologist-oncologists, and pathologists caring for patients with lymphoma with pertinent information about management issues and treatment strategies.
Contact: Tina B. Stacy, Educational Concepts Group, LLC
Phone: 770-933-1684
Fax: 770-933-1692
E-mail: tstacy@educationalconcepts.net
back to top
Real-Life Decisions: An Interactive Case-Based Symposium on the Management of Multiple Myeloma, Myelodysplastic Syndromes, and Acute Myeloid Leukemias
This program is sponsored by Research to Practice and supported by Celgene Corporation.
| Location: |
Orange County Convention Center, Hall F5 |
| Speakers: |
William I. Bensinger, MD, University of Washington, Seattle, WA
Pierre Fenaux, MD, PhD, Hôpital Avicenne/Université Paris 13, Bobigny, France
Morie A. Gertz, MD, Mayo Clinic, Rochester, MN
Farhad Ravandi, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX
B. Douglas Smith, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
Ravi Vij, MD, Washington University School of Medicine, St. Louis, MO
|
This activity will utilize case-based learning to explore the practical application of recent therapeutic advances across myelodysplastic syndromes, acute myeloid leukemias (including acute promyelocytic leukemia), and multiple myeloma. In a truly innovative approach to medical education, the program will integrate patient-level experiential video interviews to more fully elucidate the real-world challenges that routinely impact the therapeutic decision-making of community oncologists and hematologists.
Contact: Courtney Lohmann, Research to Practice
Phone: 305-400-7306
Fax: 800-960-2944
E-mail: clohmann@researchtopractice.com
back to top
New Frontiers and Evolving Paradigms in Cancer and Thrombosis: Principles, Challenges, and Solutions
This program is sponsored by the University of Massachusetts Medical School and supported by Eisai, Inc.
| Location: |
Orange County Convention Center, Room 109 B |
| Speakers: |
Samuel Z. Goldhaber, MD, Harvard Medical School, Boston, MA
Frederick R. Rickles, MD, The George Washington University School of Medicine and Health Sciences, Washington, DC
Craig Kessler, MD, Georgetown University Medical Center, Washington, DC
Alok A. Khorana, MD, University of Rochester, Rochester, NY
Michael Streiff, MD, The Johns Hopkins University School of Medicine, Baltimore, MD
|
This symposia is a case-study-based program for hematologists and oncologists that will focus on risk stratification tools and pharmacologic prophylaxis for primary and secondary prevention of venous thromboembolism (VTE) in cancer patients. The educational objectives for this program are to provide evidence-based information, new perspectives, and updates on the interface between malignancy and the coagulation cascade, national guidelines for VTE prophylaxis, and recent landmark clinical trials to improve patient outcomes.
Contact: Milo Falcon, CMEducation Resources
Phone: 678-662-1132
Fax: 678-585-9172
E-mail: milo.falcon@pharmatecture.net
back to top
Key Questions for 2010: Latest Developments in Diagnosis, Prognosis, and Treatment of Myeloma
This program is sponsored by the Annenberg Center for Health Sciences and supported by the International Myeloma Foundation.
| Location: |
Peabody Orlando Hotel, Plaza International Ballroom H |
| Speakers: |
Brian G.M. Durie, MD, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA
Phillippe Moreau, MD, University Hospital Hôtel-Dieu, Paris, France
Robert Z. Orlowski, MD, PhD, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Antonio Palumbo, MD, University of Torino and Italian Multiple Myeloma Study Group, Torino, Italy
S. Vincent Rajkumar, MD, Mayo Clinic, Rochester, MN
Jesús F. San Miguel, MD, PhD, Hospital Universitario de Salamanca, Salamanca, Spain
|
This symposium will provide participants with an overview of the most recent data from clinical trials, along with expert commentary, analysis, interpretation of findings, and discussion of implications for current clinical practice in the treatment of myeloma. The program will focus on key data in the diagnosis, prognosis, and treatment of myeloma. Current data supporting the use of novel therapeutic approaches for treating myeloma in both the frontline and relapsed settings will also be discussed, as well as the management of younger transplant-eligible patients and elderly patients. Key areas that impact therapeutic decisions, such as sequencing of therapy and safety considerations, will be addressed through exposition and discussion of appropriate patient cases to provide direct applicability to clinical practice.
Contact: Eleanor Gallelli, Clinical Care Options
Phone: 703-674-3524
Fax: 703-391-6874
E-mail: egallelli@clincialoptions.com
back to top
Strategies to Maximize Response Rates and Outcomes in Multiple Myeloma
This program is sponsored by the Penn State College of Medicine and supported by the Multiple Myeloma Research Foundation.
| Location: |
Rosen Centre Hotel, Grand Ballroom AB |
| Speakers: |
Paul G. Richardson, MD, Dana-Farber Cancer Institute, Boston, MA
Sergio Giralt, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Meletios Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece
Marivi Mateos, MD, Hospital Universitario de Salamanca, Salamanca, Spain
|
This symposium will guide clinicians in taking a more patient-specific approach to the treatment of multiple myeloma. Key issues in current management and the application of recent clinical trial data to individualized treatment decisions will be discussed.
Contact: Danielle Hesser-Watkins, Curatio CME Institute
Phone: 610-363-1619, x127
Fax: 610-363-7410
E-mail: danielle.hesser@curatiocme.com
back to top
Anticoagulant Therapy Across the Spectrum of Thromboembolic Disease
This program is sponsored by the Office of Continuing Medical Education and supported by Ortho-McNeil Janssen Scientific Affairs/Ortho-McNeil.
| Location: |
Peabody Orlando Hotel, Plaza International Ballroom DEF |
| Speakers: |
Jeffrey I. Weitz, MD, McMaster University, Henderson Research Centre, Hamilton, ON, Canada
Richard C. Becker, MD, Duke University School of Medicine, Durham, NC
Giancarlo Agnelli, MD, University of Perugia, Perugia, Italy
Michael D. Ezekowitz, MD, Jefferson Medical College, Philadelphia, PA
John A. Heit, MD, Mayo Medical School, Rochester, MN
Kenneth W. Mahaffey, MD, Duke University School of Medicine, Durham, NC
|
This symposium will take a synthetic view of recently completed clinical trials of novel oral anticoagulants for the prevention and treatment of venous and arterial thromboembolic disease. In the aggregate, these trials could have major effects on how long-term anticoagulation is approached in a variety of clinical contexts.
Contact: Carol A. Goode, The Exeter Group
Phone: 212-644-1017
Fax: 212-644-6762
E-mail: carol.goode@exeter-group.com
back to top
Changing Paradigms in T-Cell Lymphomas
This program is sponsored by the Physicians’ Education Resource and supported by Allos Therapeutics, Inc., and Eisai, Inc.
| Location: |
Rosen Centre Hotel, Grand Ballroom DE |
| Speakers: |
Francine Foss, MD, Yale Cancer Center, New Haven, CT
Eric Hsi, MD, The Cleveland Clinic Foundation, Cleveland, OH
Lauren Pinter-Brown, MD, Jonsson Comprehensive Cancer Center, Los Angeles, CA
Andrew Zelenetz, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY
John Zic, MD, Vanderbilt University School of Medicine, Nashville, TN
|
The purpose of this symposium is to provide community oncologists who treat patients with T-cell lymphomas with practical, multidisciplinary approaches that can be applied immediately to clinical practice. This program will include expert commentary outlining the essentials of T-cell lymphoma histopathology and the most current therapeutic approaches for both peripheral and cutaneous T-cell lymphomas. The tumor board sessions will provide an opportunity to reinforce best practices in diagnosis and treatment, while also giving insight into how experts manage cases when clinical data are lacking. Debate and audience questions and comments will add to the interactive nature of this program.
Contact: Dana Ritchie, Physicians’ Education Resource
Phone: 214-367-3482
Fax: 214-367-3303
E-mail: dana.ritchie@pergrouplp.com
back to top
